Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Lipton

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Bone Marrow Transplantation|March 4, 2014
Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk modelsD Kim, H-H Won, S Su, et al.
Bone Marrow Transplantation|July 3, 2007
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioningY Zaretsky, J Rifkind, G Lockwood, et al.
American Journal of Hematology|March 8, 2013
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitorsJ Cortes, R Digumarti, P M Parikh, et al.
Bone Marrow Transplantation|November 2, 2004
Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantationW Hasegawa, G R Pond, J T Rifkind, et al.
Bone Marrow Transplantation|June 1, 1997
Quality of life following bone marrow transplantation: a comparison of patient reports with population normsH J Sutherland, G M Fyles, G Adams, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical PracticeJ. E. Curtis, Y. Hao, H. A. Messner, et al.
Cancer|December 26, 2001
Illness intrusiveness among survivors of autologous blood and marrow transplantationA D Schimmer, M E Elliott, S E Abbey, et al.
Leukemia|July 31, 2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueA Hochhaus, M C Müller, J Radich, et al.
Bone Marrow Transplantation|July 14, 2015
Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2F V Michelis, H A Messner, E G Atenafu, et al.
Leukemia Research|June 2, 2005
Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patientsJ M Brandwein, V Gupta, R A Wells, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Bone Marrow Transplantation|March 4, 2014
Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk modelsD Kim, H-H Won, S Su, et al.
Bone Marrow Transplantation|July 3, 2007
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioningY Zaretsky, J Rifkind, G Lockwood, et al.
American Journal of Hematology|March 8, 2013
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitorsJ Cortes, R Digumarti, P M Parikh, et al.
Bone Marrow Transplantation|November 2, 2004
Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantationW Hasegawa, G R Pond, J T Rifkind, et al.
Bone Marrow Transplantation|June 1, 1997
Quality of life following bone marrow transplantation: a comparison of patient reports with population normsH J Sutherland, G M Fyles, G Adams, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation; Malignancy; Current Clinical PracticeJ. E. Curtis, Y. Hao, H. A. Messner, et al.
Cancer|December 26, 2001
Illness intrusiveness among survivors of autologous blood and marrow transplantationA D Schimmer, M E Elliott, S E Abbey, et al.
Leukemia|July 31, 2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueA Hochhaus, M C Müller, J Radich, et al.
Bone Marrow Transplantation|July 14, 2015
Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2F V Michelis, H A Messner, E G Atenafu, et al.
Leukemia Research|June 2, 2005
Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patientsJ M Brandwein, V Gupta, R A Wells, et al.
Pageof 11